XORTX Therapeutics Files June 2024 6-K with Executive Compensation Data
Ticker: XRTX · Form: 6-K · Filed: Jul 1, 2024 · CIK: 1729214
Sentiment: neutral
Topics: executive-compensation, regulatory-filing, 6-K
TL;DR
XORTX filed its June 6-K, showing 2023 exec pay. Check it out.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on June 28, 2024, reporting for the month of June 2024. The filing includes Exhibit 99.1, which is a Statement of Executive Compensation for the year ended December 31, 2023. Allen Davidoff, CEO, signed the report on behalf of the company.
Why It Matters
This filing provides transparency into XORTX Therapeutics' executive compensation practices for the previous fiscal year, which can be a key factor for investors evaluating company governance and financial health.
Risk Assessment
Risk Level: low — This is a routine filing reporting executive compensation and does not indicate any immediate financial distress or significant operational changes.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
- June 28, 2024 (date) — Filing date
- December 31, 2023 (date) — Fiscal year end for compensation statement
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report for the month of June 2024 and includes Exhibit 99.1, the Statement of Executive Compensation for the year ended December 31, 2023.
Who signed the Form 6-K on behalf of XORTX Therapeutics Inc.?
Allen Davidoff, Chief Executive Officer, signed the Form 6-K on behalf of XORTX Therapeutics Inc.
What period does the Statement of Executive Compensation cover?
The Statement of Executive Compensation (Exhibit 99.1) covers the year ended December 31, 2023.
What is the Commission File Number for XORTX Therapeutics Inc.?
The Commission File Number for XORTX Therapeutics Inc. is 001-40858.
Where is XORTX Therapeutics Inc. located?
XORTX Therapeutics Inc. is located at 3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1.
Filing Stats: 143 words · 1 min read · ~1 pages · Grade level 10.9 · Accepted 2024-07-01 06:00:07
Filing Documents
- f6k_062824.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 119KB
- perf.jpg (GRAPHIC) — 25KB
- 0001171843-24-003715.txt ( ) — 160KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-40858 XORTX Therapeutics Inc. 3710 – 33 rd Street NW, Calgary, Alberta, T2L 2M1 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX THERAPEUTICS INC. (Registrant) Date: June 28, 2024 By: /s/ Allen Davidoff Name: Allen Davidoff Title: Chief Executive Officer EXHIBIT INDEX 99.1 Form 51-102F6 – Statement of Executive Compensation for the year ended December 31, 2023